Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
House Science Committee hearing spotlights EPA review delays and risks to independent science as industry warns competitiveness at stake
Summary
Industry witnesses told the House Science, Space and Technology Committee that slow EPA chemical reviews and regulatory uncertainty are pushing U.S. innovation overseas, while former EPA officials and Democrats warned that cuts to the agency's independent research office risk public‑health protections.
WASHINGTON — Lawmakers probed federal chemical policy and agency capacity Tuesday as industry representatives and former Environmental Protection Agency officials sparred over whether agency changes and review delays are slowing U.S. chemistry innovation.
"America's success depends on America's chemistry," Charlotte Bertrand, senior director for chemical management, regulatory policy and strategy at the American Chemistry Council, told the House Science, Space and Technology Committee. Bertrand said EPA currently has "461 new chemicals under EPA's review" and that "90% of those have exceeded the 90‑day statutory deadline," arguing the backlog and lengthy reviews discourage domestic investment.
A former EPA official who testified, Stan Myberg, said the central question is trust in EPA science. "Independent EPA science should not be a partisan issue," Myberg said, urging Congress to preserve the Office of…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
